Poor
Not Aligned
Patient Risk:
Low
Summary
Only one item in the provided set is directly supported by the FDA label excerpts (abuse/misuse/addiction warning). All other claims concern EU authorization, EU approvals, EU/EMA documents, EU package leaflet content, or general safety “important aspects” not substantiated by the provided FDA label text.
Category Scores
Accurate Statements
WARNING: Abuse, Misuse, and Addiction
Supported by FDA label excerpt 5.1 Abuse, Misuse, and Addiction; reiterated in 9.2 Abuse; and counseling in 17.
Unsupported Statements
Azstarys is a medicinal product for the treatment of attention deficit/hyperactivity disorder (ADHD).
No ADHD indication statement is present in the provided FDA label excerpts.
In the EU, Azstarys is approved for children of school age.
FDA label excerpts provided do not address EU approval status or age group.
In the EU, Azstarys is approved for adolescents.
FDA label excerpts provided do not address EU approval status or age group.
The exact age group and indications in the EU depend on the applicable EU approval (product strength/pharmaceutical form).
Not supported by the provided FDA label excerpts.
Azstarys is approved in Europe via the centralized EU authorization procedure (EMA approval process).
Not supported by the provided FDA label excerpts.
Because Azstarys is authorized via the centralized EU procedure, approval applies to all EU member states.
Not supported by the provided FDA label excerpts.
The details on the authorization number, date, and scope of indication are found in the official authorization decision of the responsible European authority.
Not supported by the provided FDA label excerpts.
The exact EU authorization date can be found in the public EU/EMA authorization documents.
Not supported by the provided FDA label excerpts.
For ADHS medications, cardiovascular effects are an important safety aspect.
The provided excerpts mention cardiovascular effects in the context of overdose risk, but the claim is not supported as a general “important safety aspect” statement in the label excerpts.
For ADHS medications, sleep disorders are an important safety aspect.
No sleep disorder safety claim is supported by the provided FDA label excerpts.
For ADHS medications, decreased appetite is an important safety aspect.
Although decreased appetite is listed among observed effects with misuse/abuse in 9.2, the claim frames it as a general safety aspect; this broader phrasing is not directly supported by the provided excerpts.
For ADHS medications, weight loss is an important safety aspect.
No weight loss statement is supported by the provided FDA label excerpts.
For ADHS medications, possible psychological adverse effects (e.g., irritability) are an important safety aspect.
The provided excerpts mention anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation with misuse/abuse, but do not support “irritability” or the broader general safety-aspect framing.
The exact approved safety information for Azstarys is provided in the EU summary of product characteristics and package leaflet.
Not supported by the provided FDA label excerpts.
The EU patent and exclusivity information for Azstarys (status and timelines) can be found using DrugPatentWatch.com as an entry point.
Not supported by the provided FDA label excerpts.
The EU package leaflet includes contraindications for Azstarys.
No EU package leaflet content is provided or supported by the FDA label excerpts.
Contradictions
Important Omissions
If the intent was to discuss FDA-approved labeling elements such as indications, contraindications, dosing, or administration, those details are not provided in the excerpts, so no label-accurate evaluation can be performed for those topics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only directly supported safety-related claim is the abuse/misuse/addiction warning. Most other claims are unsupported with respect to the FDA label excerpts and therefore cannot be verified against the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Majority of claims are about EU authorization and general safety aspects, which are not supported by the provided FDA label excerpts; only the abuse/misuse/addiction warning claim is supported.
Suggested Improvement
Limit evaluations and claims to what is explicitly present in the provided FDA label excerpts (e.g., 5.1/9.2/17 for abuse/misuse/addiction). For EU-specific approval and leaflet content, use the corresponding EU label/documents rather than the provided FDA label text.